By abhat@reaganud… on
ClinicalTrials.gov URL
https://clinicaltrials.gov/ct2/results?cond=&term=celularity&cntry=&state=&city=&dist=&Search=Search&recrs=a&recrs=b&recrs=c&recrs=d&recrs=f&recrs=k
COVID-19 Information

Celularity Announces FDA Clearance of IND Application for CYNK-001 in Coronavirus, First in Cellular Therapy - Celularity Inc., a clinical-stage company developing allogeneic cellular therapies from human placentas, has announced that the U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application for the use of its proprietary CYNK-001 in adults with COVID-19. With this, Celularity will commence a Phase I/II clinical study including up to 86 patients with COVID-19. 

Other companies mentioned: Sorrento Therapeutics, United Therapeutics/Lung Biotechnology

Stage
Phase 1
Company Type
Late Onset Intervention
Early Onset Intervention